Presentation at the Institut Pasteur
"Addressing the malaria eradication agenda with next-generation antimalarials: Medicines for Malaria Venture’s R&D portfolio"
The presentation will elaborate on MMV’s drug research and development portfolio, which focuses on medicines that meet the following criteria: efficacy against drug-resistant strains of Plasmodium falciparum, potential for intermittent treatments (infants and pregnant women), safety in very young children, safety in pregnancy, efficacy against Plasmodium vivax (including radical cure), efficacy against severe malaria, and transmission-blocking properties.
Didier will also discuss current combination therapies and new drug candidates that target the malaria eradication agenda, outlining their respective target product profiles and target candidate profiles. The presentation will conclude with a look at the current challenges to eradicating malaria, and the urgent need to develop next-generation antimalarials that will be able to address drug resistance, block transmission and put an end to relapsing malaria.